Chamberlain moves under CCC umbrella
pharmafile | June 24, 2011 | News story | Medical Communications | medical communications, medical communications agency, medical communications news
Health PR specialist Chamberlain Communications Group is to come under the umbrella of Chandler Chicco Companies (CCC) as a prelude to the expansion of both brands.
Both are owned by inVentiv Health and have operated in silos until now. Chamberlain president Jonathan Wilson continues in his post and will play what the company calls a “critical role in expanding CCC’s global footprint” along with CCC Europe MD Fiona Hall.
“Over the past several years we have significantly grown our global business and this new alignment will allow us to identify new opportunities and drive further growth,” said Wilson.
Based in New York and London, Chamberlain has 60 staff and its accounts include Abbott Laboratories, Boehringer Ingelheim, Eli Lilly, Novartis and Pfizer.
It comprises Chamberlain Healthcare PR and newly-launched agency SharedVoice PR, which focuses on small-to-medium-sized health businesses.
Wilson said he was looking forward to “exploring synergies between the brands to generate even more compelling business strategies for our clients”.
There are no plans for Chamberlain or SharedVoice to change their names. Instead, they will operate as separate businesses within CCC’s global network, with Wilson reporting directly to CCC founder Bob Chandler.
“Nowhere else in the world will a client be able to tap a dedicated communications network with more pure-play healthcare expertise,” said Chandler.
“This provides us unprecedented resources and momentum to lead the healthcare marketplace in communicating the most complex science, health and wellness issues of our time,” he added.
Founded in 1993, Chamberlain promotes its point of difference as a science-based approach to health comms: “We rely on science as the backbone of the brand promise,” its website says.
Before this move, CCC had around 300 staff in 10 businesses worldwide, including Chandler Chicco Agency (CCA), Biosector 2 and Litmus.
Last month CCA won the pharma category at the EMEA Sabre Awards for the launch of the chronic migraine indication in the UK for Allergan’s Botox.
Adam Hill
Related Content
Synergy Vision MD appointed as trustee of the Cystic Fibrosis Trust
Managing director of Synergy Vision Ffyona Dawber has been appointed to the Cystic Fibrosis Trust’s …
The mutual benefit of becoming one of Britain’s best workplaces
Imagine a company with a 100%-satisfied workforce. What could a team of such fulfilled employees …
